Psychiatr Genet 2001, 11:71–78 PubMedCrossRef 55 Ekelund J, Henn

Psychiatr Genet 2001, 11:71–78.PubMedCrossRef 55. Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lonnqvist J, Peltonen L: Replication of 1q42 linkage in finnish schizophrenia pedigrees. Mol Psychiatry 2004, 9:1037–1041.PubMedCrossRef 56. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, et al.: A genome-wide association study of type 2 diabetes in finns detects multiple susceptibility

variants. Science 2007, 316:1341–1345.PubMedCentralPubMedCrossRef 57. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, Clarke R, Collins R, Franzosi MG, Tognoni G, Seedorf U, Rust S, Eriksson P, Hamsten LXH254 price A, Farrall M, Watkins H, Consortium P: Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked snps in the anril locus on chromosome 9p. Hum Mol selleck Genet 2008, 17:806–814.PubMedCrossRef 58. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA: Non-codingrna sequence variations in human chronic lymphocytic leukemia and colorectal cancer.

Carcinogenesis 2010, 31:208–215.PubMedCrossRef

59. Haiman CA, Le Marchand L, Yamamato J, Stram DO, Sheng X, Kolonel LN, Wu AH, Reich D, Henderson BE: A common genetic risk factor for colorectal and prostate cancer. Nat Genet 2007, 39:954–956.PubMedCentralPubMedCrossRef 60. Ferro P, Catalano MG, Dell’Eva R, Fortunati N, Pfeffer U: The androgen receptor cag repeat: a modifier of carcinogenesis? Mol Cell Endocrinol 2002, 193:109–120.PubMedCrossRef 61. Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C: Gender influences the class iii and v beta-tubulin ability PDK4 to predict poor outcome in colorectal cancer. Clin Cancer Res 2012, 18:2964–2975.PubMedCrossRef Competing interests None of the Authors has any potential financial conflict of interest related to this manuscript. Authors’ contributions LLJ, GLB and ZL designed the study. LLJ, SRF, LYD, PXM, LZH, BP, ZXF and ZhDX performed genotyping. LLJ, SRF and GLB conducted statistical analysis. LLJ and ZL wrote the manuscript. All authors read and approved the final manuscript.”
“Introduction The use of dose escalation in radiation therapy, with doses ranging from 74 to 80 Gy, has shown an improvement in the outcome of prostate cancer when compared with conventional doses, as reported in large retrospective studies [1, 2] and in some prospective randomized trials [3–8].

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>